Objectives: Outpatient parenteral antibiotic therapy (OPAT) is an effective treatment strategy for a wide variety of infections as long as clinical risk is minimized by conforming to practice guidelines. However, its cost-effectiveness has not been established in the setting of the UK National Health Service. We examined the clinical efficacy and cost-effectiveness of an OPAT service based in a large UK teaching hospital, predominantly using the outpatient 'infusion centre' and patient/carer administration models of service delivery.
Introduction
In the UK over recent years there has been increasing interest in developing programmes to deliver care closer to home for conditions that have traditionally been treated in hospital, driven by a number of factors including cost considerations, patient preference and the rise in hospital-acquired infections. 1 One area where this is applicable is in the administration of home or outpatient intravenous antibiotic therapy for patients who require parenteral therapy but are well enough not to require hospital admission. This approach was first used in the 1970s for patients with cystic fibrosis, 2 and its use internationally has increased substantially since then. 3, 4 Outpatient parenteral antibiotic therapy (OPAT) is now established in many parts of the world as an effective approach for a wide variety of infections, facilitated by the development of newer antibiotics with longer half-lives. 4, 5 OPAT in the UK has developed more slowly, but is now becoming more widespread. 6 -11 Although OPAT clearly has the potential to reduce the number and duration of hospital admissions, few studies have examined its cost-effectiveness in detail, 12 -15 and to date none in the setting of the UK National Health Service (NHS). While OPAT is likely to result in significant savings due to reduced use of inpatient beds, there are also substantial costs incurred in establishing a specialist service of high quality and with minimal clinical risk. The use of OPAT continues to expand both nationally and globally, and it is important to have clear evidence of both clinical efficacy and financial benefits. We set out to examine this in detail in the setting of the UK NHS.
Patients and methods

The OPAT service
The Sheffield OPAT service was established in 2006 in the regional Infectious Diseases Unit, based in a large teaching hospital. It is run by a multidisciplinary team comprising infectious diseases physicians, a specialist nursing team, a pharmacist and a microbiologist. The service predominantly uses the outpatient 'infusion centre' and patient/carer administration models of antibiotic delivery, rather than administration in the patient's home by a visiting nurse. There are two main groups of patients: those on short-term antibiotics for skin and soft tissue infections, who attend the OPAT Unit once daily for treatment and review; and those requiring prolonged courses, who may either attend once or twice daily, or learn to self-administer their treatment, predominantly using antibiotic infusions via a peripherally or centrally inserted central venous catheter: selfadministration (or administration by a family member or carer) also enables patients on multiple daily doses to receive their treatment out of hospital, something that would not be possible using the 'infusion centre' model of service delivery alone. All patients on prolonged antibiotic courses have a medical and nursing review at least weekly. There is 24 h access to advice or admission as necessary for all OPAT patients.
Patients are enrolled into the OPAT service after medical and nursing assessment if they meet a number of pre-defined criteria: aged .16 years; an infection requiring intravenous antibiotics, either for a short course or with a pre-determined treatment duration; antibiotic regimen suitable for administration through OPAT; medically stable; adequate venous access; capable of understanding and consenting to OPAT; and safe social circumstances with access to a telephone.
Data collection
A database was set up prior to commencement of the service to record prospectively patient demographics, clinical condition, antibiotics and duration of treatment, type of intravenous access, clinical outcome and complications. Using this database, we retrospectively reviewed all OPAT episodes of care for 2 years from January 2006. The key outcomes recorded were range of conditions treated, duration of OPAT and prior inpatient antibiotics, clinical outcomes on completion of intravenous therapy and complications. Patient notes were also reviewed where necessary to obtain complete data. In addition, patients were routinely given an anonymous feedback questionnaire at the end of parenteral antibiotic therapy.
Economic evaluation
The economic evaluation calculates the costs of OPAT and conventional care, but does not combine these with outcomes in the form of a summary statistic, such as an incremental cost-effectiveness ratio. However, the incremental costs are presented together with several outcome measures to allow decision makers to make an assessment of relative cost-effectiveness; such an approach is termed a cost-consequences analysis. This approach was chosen as a single outcome measure that captured all important elements of the service was not available.
Costs were estimated from the NHS perspective as this is most appropriate for planning services within a fixed NHS budget. Costs are made up of two components: the delivery of the OPAT service and the delivery of inpatient care. Resource use within the OPAT service is based on the management accounts of the service, whilst inpatient care resource use is based on inpatient days. For the OPAT patients, actual admissions were used. For conventional care, the length of inpatient stay was assumed to be the same duration as the length of OPAT care, and diagnosis was also assumed to be the same.
The total costs of the OPAT service were calculated using actual costs of staffing and running the service over this 2 year period. Added to this were the costs of admissions to hospital (calculated as described below) following any adverse events caused through OPAT that would not have occurred had the patient been an inpatient, giving a total cost for OPAT therapy. Prior to commencement of clinical activity, there was a set-up phase of 3 months during which costs were incurred, mainly for staffing. It was assumed that the likely lifetime of the service before any further substantial redesign was necessary was 5 years. Using the England and Wales recommended discount rate of 3.5%, the set-up costs were spread over the lifetime of the service using annuitization to produce an equivalent annual cost. Two years of this have been included in the overall costs of OPAT over the 2 year study period.
Unit costs for inpatient days were based on the healthcare resource group (HRG) of each patient, which in turn is based on diagnosis. Unit costs for hospitalizations were Sheffield Teaching Hospital's (STH) Directorate of Communicable Diseases average cost per day for each HRG. Two sensitivity analyses were undertaken with respect to these unit costs, as it was considered that uncertainty was greatest around the generalizability of costs and the valuation of an appropriate cost per day. First, national average non-elective costs per day were used for each diagnosis, which are slightly lower than those seen in an Infectious Diseases Unit, and which may better represent the overall impact of OPAT services nationally. Secondly, a cost per day was estimated for patients requiring minimal clinical care as an inpatient for each diagnosis, as this may better reflect this patient group, which can be treated on an outpatient basis. This cost was proxied by estimating the cost per day for all non-elective HRGs and then allocating the lowest cost per day within each HRG chapter to the OPAT diagnoses that belong to that chapter (STH and national costs were based on HRG version 3.5). So, for cellulitis (HRG v 3.5 code J42) the STH cost was £366 per day (2007/8 prices) compared with a national average of £324, and a lowest cost per day for HRG v 3.5 code J99 (Complex Elderly with a Skin, Breast or Burn Primary Diagnosis) of £242. STH costs were 2007/8 costs, whilst national costs were for 2005/6 inflated to 2007/8 using annual NHS inflation uplifts (4% and 2.5%).
Results
Patient demographics and clinical activity
In the 2 year study period there were a total of 334 episodes of care in 296 patients (Table 1) . Skin and soft tissue infections accounted for 59% of episodes (198: 186 cellulitis, 10 erysipelas, 1 wound infection and 1 thrombo-phlebitis), with a mean duration of OPAT of 4.9 days (range 1 -46). For cellulitis episodes (n¼ 186), the mean duration of OPAT was 4.8 days, and mean duration of inpatient antibiotic therapy prior to discharge to OPAT was 2.0 days (range 0-21). The mean total duration of parenteral antibiotic therapy (i.e. inpatient stay plus number of subsequent days of OPAT) was 6.8 days; the average length of inpatient stay for patients with cellulitis within our hospital trust for the year 2005 -06, i.e. immediately prior to the establishment of the OPAT service, was 7.6 days.
Patients with skin and soft tissue infections were referred from the infectious diseases or medical wards (49.5%), or directly from the emergency admission wards (47.5%). A small number of patients (3%) self-referred to OPAT, having previously received treatment via OPAT for a previous episode of cellulitis or erysipelas. Patients were assessed prior to acceptance onto OPAT by a physician or specialist nurse, either directly or through a telephone referral system. All patients with skin and soft tissue infections attended daily for outpatient therapy with intravenous ceftriaxone (197/198) or daptomycin (1/198); an additional oral antibiotic was added in 29 (15%) episodes (25 clindamycin, 3 flucloxacillin and 1 erythromycin). In all but five episodes, peripheral intravenous access was used (Table 1) . A Hickman line was used in three episodes of soft tissue sepsis, all occurring in one patient who had recurrent infections and was given prolonged courses of antibiotics. Two patients were given peripherally inserted central cannulas (PICCs): one of these had a prolonged course of antibiotics post-removal of a pacemaker, and the other had severe streptococcal sepsis. All patients were reviewed daily by the specialist nurses, and whenever necessary by a physician, e.g. when their infection had improved sufficiently to switch to oral antibiotic therapy.
Other non-skin/soft tissue infections accounted for 41% (136) of episodes ( Figure 1 ). The mean duration of OPAT in this group was 22.5 days, ranging from 1 day (e.g. for completion of intravenous therapy for meningococcal sepsis, typhoid fever or pneumonia) to 163 days: the longest courses were administered for the treatment of tuberculosis requiring parenteral streptomycin (163 days), endocarditis (72 days), discitis (76 days), actinomycosis (157 days) and cerebral Nocardia infection (120 days). A range of intravenous access types was used (Table 1 ). In 38 episodes (29 patients; 1572 days of OPAT; range of OPAT duration 7 -157 days) antibiotics were administered by the patient or a relative at home after a formal training programme; these patients attended the OPAT unit at least weekly for medical and nursing review.
The total number of bed days saved through OPAT activity over the 2 year period was 4034 ( Figure 2 ). Although skin and soft tissue infections accounted for 59% of episodes overall, they accounted for only 24% of the total bed days saved (Table 1) , which reflects the often prolonged courses given to patients with other diagnoses such as endocarditis, bone and joint infection, brain abscesses, etc. Patients were referred from a wide range of clinical specialities across the acute hospital trust. 
Clinical outcomes
Clinical outcomes were documented on the database on completion of intravenous antibiotic therapy by the OPAT specialist nurses ( Figure 3) . A total of 291/334 (87%) of patients were recorded as having been cured or improved at that point [182/ 198 episodes of skin and soft tissue infection (92%) and 109/ 136 episodes involving other diagnoses (80%)]. Twenty-one episodes (6.3%) terminated in readmission: six unrelated to OPAT; six due to inappropriate referral; one for symptom control; three patients with non-resolving soft tissue sepsis; one patient with deep sepsis who was failing to make an adequate clinical response to antibiotics; and four patients who developed a complication of OPAT. Of these latter four, one had an antibiotic reaction and was readmitted for alternative intravenous therapy, one developed a line infection, one sustained a fractured humerus after falling while travelling to the OPAT unit and required readmission for 28 days to stabilize her fracture and for social reasons, and the final patient cut off the end of her PICC line while self-administering antibiotics, and had to be readmitted for it to be replaced: she remained in hospital for 12 days subsequently to complete her antibiotic therapy. Eleven episodes were recorded as having resulted in 'no change': 10 of these involved the administration of prophylactic antimicrobial therapy for invasive fungal infection or visceral leishmaniasis in immunosuppressed patients, while the last was a patient with recurrent cellulitis who was discharged to OPAT following a prolonged admission but was switched to oral antibiotics after 1 day following a further clinical review. In 11 episodes 
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OPAT was terminated because of a change of plan: 3 of these involved a highly complex patient with recurrent methicillinresistant Staphylococcus aureus (MRSA) bacteraemia, while a further 4 were patients with cellulitis who responded to intravenous antibiotics initially but then required surgical drainage of superficial collections, with subsequent oral antibiotics. The remaining four patients had a range of complex non-skin/soft tissue infections initially treated via OPAT, with a subsequent change to the management plan. Two patients developed drug reactions on OPAT: one was readmitted for alternative parenteral therapy (as noted above), while one developed a pruritic rash on teicoplanin and was switched to ceftriaxone via OPAT with subsequent improvement. Two patients developed Clostridium difficile diarrhoea during their intravenous antibiotic therapy, and a further patient had diarrhoea on starting OPAT, and was subsequently found to have C. difficile toxin on stool testing. This did not result in a change of parenteral antibiotic therapy in any of these patients, who all responded promptly to planned antibiotic discontinuation+oral metronidazole without the need for readmission.
Longer term follow-up data were not collected routinely on the database. The notes of 62 randomly selected patients with skin/soft tissue infections were reviewed retrospectively to obtain follow-up data. The mean period of follow-up was 27.8 days (range 4 -122). A total of 61/62 (98.4%) patients were recorded as having been cured or improved at follow-up. One patient with facial erysipelas received 1 week of intravenous therapy (3 days via OPAT) before being switched to oral antibiotics, but then developed increasing erythema and restarted intravenous therapy 1 week later, again via OPAT. She improved again and was switched to oral therapy after 3 days. At subsequent follow-up after 22 days she was recorded as having been cured. She had a further episode of facial erysipelas 6 months later and again was treated via OPAT with full recovery. In addition to this patient, a further seven of the 198 patients presenting with soft tissue sepsis had at least two episodes of infection at the same site within the study period (five patients with two episodes and two patients with four episodes).
Patients' views were assessed by the routine administration of a questionnaire at the end of parenteral therapy. Data were available between the start of the service in January 2006 and the end of September 2008; it was not possible to separate out questionnaires completed during the study period due to the anonymous nature of the questionnaires. Of 449 patients treated via OPAT during this time, 276 responded (61%). A total of 272 respondents (98.6%) rated the service as very good or excellent, 1 as good and 3 as average; 275 (99.6%) stated that they would choose the OPAT service again.
Cost-effectiveness
The total cost of establishing and running the OPAT service over the 2 year study period was calculated using actual cost data, and is shown in Table 2 . The total cost of delivering OPAT over the 2 year period was £612306, i.e. just over £300000 per year. This also includes an allocation for the cost of the set-up phase before clinical activity commenced (see the Patients and methods section for explanation), and also costs relating to two readmissions where it was deemed that these complications would not have occurred had the patients been treated as inpatients: the patient who fractured her humerus and was readmitted for 28 days; and the patient who cut off the end of her PICC line and was readmitted for 12 days. The other 19 readmissions during the study period were not included in this part of the analysis as it was assumed that these complications would have happened whatever the treatment method used, and would have resulted in increased length of stay for patients already in hospital.
Staffing costs accounted for 42% of the total cost of OPAT, mainly the OPAT specialist nursing team. Non-pay costs (56% of total) comprised drugs, consumables and equipment, and also the overhead and support costs: these included laboratory services, pharmacy, physiotherapy, patient transport and direct costs of running the unit. The overhead and support costs were Total cost of delivering OPAT (2 years) 601042
Cost of two inpatient admissions 11 264
Total cost (2 years) 612306
Total cost per year 306153 a Total set-up cost £22837; amount apportioned based on annual equivalent costs using a 5 year time horizon and a discount rate of 3.5%. b Overhead and support costs at 45% of total cost of service (based on outpatient reference cost profile).
derived from the 2006/7 reference cost profile for our Infectious Diseases Outpatient Department, and equate to 45% of the total cost of the outpatient service (total minus the cost of the two inpatient admissions), i.e. £601 042. Theoretical costs of conventional inpatient therapy were calculated for the 334 patient episodes using our own directorate costs per day for each HRG to which the diagnosis belonged and multiplying this by the number of days of OPAT for each diagnosis. As an example, there were two episodes of treatment for bacterial pneumonia, with a total of eight OPAT days. The HRG cost for our unit for D14 ( pneumonia; HRG v 3.5) is £388, and thus the estimated cost of inpatient care for these episodes is £388 multiplied by 8, i.e. £3104. Inpatient costs were not discounted as they all occurred within 1 year of admission.
Using this method, the total cost of equivalent inpatient care for the 334 episodes using our own directorate costs was £1 502769 (Table 3) . We used the same method to calculate costs using national average costs, since Infectious Diseases Units generally have higher costs per day for care due to the specialist nature of the service and requirement for isolation facilities: the total cost for inpatient care for this patient cohort was £1 312537 using these costs. One further set of costs was derived to calculate the minimum costs of inpatient care for these diagnoses, since OPAT patients are by definition a relatively fit group compared with the average hospital inpatient: using the minimum costs for each HRG chapter for each diagnosis, the total theoretical cost of inpatient care for our patient cohort was £1 005676. Thus even using the minimum possible cost for inpatient care, OPAT resulted in a considerable cost saving.
Discussion
In the UK in recent years there has been increasing emphasis on increasing care in the community, by reducing length of stay for inpatients and, where possible, avoiding admission altogether. The use of OPAT to treat patients who require intravenous antibiotic therapy but do not require hospitalization is in keeping with this goal. This study provides further evidence of the safety and clinical effectiveness of OPAT, and it is very likely that this mode of treatment delivery will be used increasingly in future in the UK for the delivery of parenteral antibiotics for suitable patients. This service predominantly used the outpatient ('infusion centre') and patient/carer administration models of OPAT delivery; other groups have also demonstrated the efficacy of home therapy using the visiting nurse model. 6, 16 The service described here is based in a specialist Infectious Diseases Unit in a large teaching hospital, and was developed with clear protocols and standards for medical and nursing supervision, in line with existing national and international practice guidelines; 4, 7 this is critical to ensure minimal clinical risk for patients who have a lower level of supervision than with inpatient care. 17, 18 The success rate at the end of intravenous therapy was high and the rate of complications low, with a readmission rate during intravenous therapy of only 6.3%; this is equivalent to, or lower than, rates reported in previous studies. 8, 9, 19 Long-term follow-up for a proportion of patients with cellulitis showed excellent outcomes at a mean follow-up of 27.8 days. Although the database did not include prospective data on hospitalacquired infections, there were only two episodes of C. difficile Table 3 . diarrhoea that developed in patients undergoing OPAT, and no patients who acquired MRSA. Both patients with C. difficile diarrhoea had been hospitalized prior to referral to OPAT, and hence it is difficult to determine the relative contributions of inpatient care and OPAT. 20 Data on the effect of OPAT on hospital-acquired infections generally are limited but suggest that rates of infection are reduced compared with the inpatient setting, presumably due to a combination of reduced exposure and improved patient fitness compared with the inpatient population. 21, 22 Similarly, although there may be theoretical concerns about using once-daily broad-spectrum antibiotics for infections that require a narrower spectrum of antimicrobial activity, data on emergence of resistant organisms, such as extended-spectrum b-lactamase-producing Gram-negative organisms, in patients undergoing OPAT are currently limited, and there is a need for further studies to address this issue.
Skin and soft tissue infections, mainly cellulitis, accounted for 59% of episodes in the 2 year study period. The mean total duration of intravenous antibiotic therapy in OPAT patients treated for cellulitis was less than the average length of stay for cellulitis in our hospital trust. While OPAT patients are likely to have fewer co-morbidities than inpatients with cellulitis, this observation suggests that the level of medical supervision provided for OPAT was adequate to prevent unnecessarily protracted antibiotic courses. This is supported by a randomized controlled trial of OPAT versus inpatient therapy for cellulitis that demonstrated no difference in length of treatment, 16 as well as by other observational studies. 9 However, this does require a flexible approach to patient reviews, rather than pre-defined intervals between patient assessments. It is also possible that patients treated via OPAT had less severe infections, resulting in shorter parenteral antibiotic courses. There is a theoretical risk that where an OPAT service exists, patients may be referred who could be treated adequately with oral antibiotics: however, in the context of this study, this seems unlikely since all patients (excluding the small number that self-referred) were referred to OPAT by a physician and then reviewed by an experienced Infectious Diseases nurse and physician prior to being accepted for OPAT.
In 41% of episodes, patients were treated for diagnoses other than soft tissue sepsis. There was a wide range of diagnoses and lengths of treatment. Patients receiving the longest antibiotic courses, for diagnoses such as endocarditis, bone and joint infection or cerebral actinomycosis, tended to self-administer their therapy. The 38 episodes where patients (or carers) administered antibiotics in their own homes (11% of total OPAT episodes) accounted for a total of 1572 days of OPAT, or 39% of the total OPAT days. This model of delivery was advantageous in that, contrary to nurse-administered therapy where patients attended daily for treatment, these patients attended once or twice per week, with resultant time and cost savings, as well as benefits for the patients in terms of flexibility and control, and the ability to fit their treatment round work and other commitments. This is reflected in the very positive patient feedback. Our own data, and a larger study over a 13 year period, demonstrate that patient/carer-administered therapy is as safe as healthcare professional-administered treatment for selected patients. 23 Patients who self-administered were also able to give multiple doses in a day, e.g. five patients self-administered flucloxacillin four times per day for deep-seated Staphylococcus infections (four for bone and joint infection, one for endocarditis), and others gave multiple daily doses of meropenem, amoxicillin and gentamicin as indicated for their infections.
Thus we have shown that the OPAT service model used in our centre is safe and clinically effective, with low rates of complications/readmissions and high levels of patient satisfaction. However, it is important to demonstrate that this highly specialized service is also cost-effective in the context of our healthcare system, based not only within an Infectious Diseases Unit, as here, but also in other service settings. Previous reports from the UK have provided preliminary data to suggest that this is the case, 10,11,24 but none to date has analysed the relative inpatient and OPAT costs in detail. Here, the real costs of the OPAT service over the 2 year study period were calculated, and compared with estimated costs of equivalent inpatient care for these patients using costs of managing these conditions in our Infectious Diseases Unit. OPAT cost 41% of the estimated equivalent inpatient cost. Sensitivity analyses were undertaken to assess the impact of uncertainty relating to unit costs, overhead rates and adverse events in the inpatient therapy calculations. Thus, costs were calculated using national average costs, and the lowest possible cost per day for each HRG. National average costs are not specific to Infectious Diseases Units, which are likely to be more expensive than other units because of the increased costs of managing patients in single isolation rooms, and hence this calculation was included to make the findings more applicable to a wider range of acute hospital trusts across the UK. This comparison showed OPAT to be 47% of the cost of inpatient care. Finally, the lowest possible cost per day for inpatient care was calculated. This cost is a proxy for a day in hospital for a patient needing minimal clinical care, and assumes that this directly replaces the OPAT care. Clearly many patients will require more intense inpatient care prior to any maintenance therapy; however, this would be the same for OPAT patients and, therefore, whilst the unit cost may underestimate initial treatment, it will be underestimated equally in both arms of the study. Even with this minimal inpatient cost analysis, OPAT was shown to be 61% of the cost of inpatient care.
It should be noted, however, that the economic analysis within the study is focused on just two alternatives and that other uses of the same resources could be even more costeffective. Individual healthcare providers therefore need to assess whether an OPAT service is the best service development option open to them in this clinical setting. Furthermore, whilst our analysis shows that OPAT is likely to be a cost-effective use of resources, the financial incentives produced by alternative healthcare systems will have an impact on the financial viability of their development. So, in countries with activity-based prospective payment systems, if the outpatient/home activity is not fully reimbursed, the development of such a service could be loss-making to the service provider.
Thus using a range of comparator inpatient costs, OPAT was cost-effective. Furthermore, this model examined only direct costs of patient care in two settings. OPAT results in further indirect benefits and cost savings, e.g. income to the acute trust from further admissions into the bed vacated through the use of OPAT, reduced cancellations of operations, improvements in efficiency of bed use and patient flow, e.g. from the Accident and Emergency Department to an appropriate ward, and so on. Calculations of the financial and other consequences of these indirect outcomes of OPAT would require complex modelling and are beyond the scope of the present study, but add to the weight of evidence supporting the cost-effectiveness of OPAT in this healthcare setting.
In this analysis, a number of assumptions were made. First, it was assumed that the number of days of OPAT equals the number of inpatient bed days saved, or the number of days patients would otherwise have been in hospital. Since both the inpatient Infectious Diseases service and OPAT are managed by the same group of Infectious Diseases specialists, this would seem a reasonable assumption. In both care settings, patients with skin/soft tissue infections were reviewed daily by an experienced Infectious Diseases nurse; although patients being treated via OPAT had less frequent physician reviews than inpatients with skin/soft tissue infections, the duration of antibiotics for patients receiving OPAT for cellulitis was no greater than the average inpatient stay for cellulitis for our hospital. A previous study has shown that patients being treated for cellulitis via OPAT and having nurse-led management have shorter courses of intravenous antibiotics than when reviewed by physicians. 9 For longer term patients on OPAT who were self-administering antibiotics, medical and nursing reviews were less frequent (although at least weekly, with immediate access to advice/ review/readmission as necessary), but these patients invariably had a pre-defined treatment duration, which would have been the same whether they were treated in hospital or via OPAT.
Secondly, it was assumed that costs relating to the patient's inpatient stay (where there was one) prior to referral to OPAT would be identical in the OPAT and inpatient calculations. Finally, only two readmissions were included in the overall costs of the OPAT service, since it was assumed that the other readmissions were not related directly to OPAT and would therefore have affected both arms of the analysis equally.
In conclusion, this study demonstrates that this model of OPAT is safe and clinically effective with low levels of complications and high levels of patient satisfaction. OPAT results in lower costs when compared with equivalent inpatient care in the UK. With increasing emphasis on moving care into the community, the use of OPAT is likely to increase, and the results of this study suggest that OPAT is a viable alternative to inpatient care for a wide range of infections in suitable patients, as long as clinical risk is minimized by conforming to existing practice guidelines.
